Particulars (Rupees in Crores.) | Mar-2025 | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 |
---|---|---|---|---|---|
Gross Sales | 792.51 | 758.86 | 690.56 | 679.18 | 741.98 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 792.51 | 758.86 | 690.56 | 679.18 | 741.98 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 7.5 | 7.19 | 8.52 | 2.44 | 4.6 |
Total Income | 800.01 | 766.05 | 699.07 | 681.62 | 746.58 |
Total Expenditure | 712.42 | 682.13 | 637.99 | 687.72 | 796.61 |
PBIDT | 87.59 | 83.92 | 61.09 | -6.11 | -50.03 |
Interest | 30.08 | 30.67 | 25.03 | 23.06 | 20.6 |
PBDT | 57.51 | 53.25 | 36.06 | -29.17 | -70.62 |
Depreciation | 33.1 | 33.35 | 31.94 | 29.6 | 28.38 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 21.76 | 19.13 | 7.98 | 5.97 | 3.73 |
Deferred Tax | -14.21 | -14.63 | -15.8 | -23.18 | -0.52 |
Reported Profit After Tax | 16.86 | 15.4 | 11.94 | -41.56 | -102.22 |
Minority Interest After NP | 4.1 | 6.28 | 4.6 | 1.66 | 0.23 |
Net Profit after Minority Interest | 12.76 | 9.12 | 7.35 | -43.23 | -102.44 |
Extra-ordinary Items | -0.65 | -0.17 | -1.95 | -13.88 | -61.6 |
Adjusted Profit After Extra-ordinary item | 13.41 | 9.29 | 9.3 | -29.35 | -40.84 |
EPS (Unit Curr.) | 0.51 | 0.37 | 0.29 | -1.74 | 0 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 50.06 | 49.92 | 49.89 | 49.89 | 49.89 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 11.05 | 11.05 | 8.84 | -0.89 | -6.74 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 2.12 | 2.02 | 1.72 | -6.11 | -13.77 |
Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.